diltiazem

(redirected from Cardizem la)
Also found in: Dictionary, Medical.
Related to Cardizem la: diltiazem hydrochloride, Tiazac
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • noun

Synonyms for diltiazem

a calcium blocker (trade name Cardizem) used in treating hypertension or angina or heart failure

References in periodicals archive ?
Watson said that the company plans to launch its generic Cardizem LA with immediate effect.
Watson intends to launch its generic version of Cardizem LA immediately.
Glasser reported on 311 patients with chronic stable angina pectoris who participated in a 13-week double-blind placebo-controlled trial in which they took Cardizem LA or placebo at night or in the morning.
Citing IMS Health as a source, Watson notes that Cardizem LA posted sales in the United States of about $94 million for the 12 months ended December 31, 2009.
The Company currently markets Niaspan and Advicor for the treatment of cholesterol disorders, Azmacort for the treatment of asthma, Cardizem LA for the treatment of hypertension and angina, and Teveten and TevetenHCT for the treatment of hypertension.
Biovail"), which is the holder of the New Drug Application for Cardizem LA, initiated a patent infringement lawsuit against the Company for the 420mg strength in the U.
In May 2005, the Company acquired from Biovail Corporation's affiliates an exclusive license to Teveten (eprosartan mesylate) and Teveten HCT (eprosartan mesylate/hydrochlorothiazide) and obtained exclusive sales and marketing rights to Cardizem LA (diltiazem hydrochloride) in the United States.
000s) Q1/05 Revenues Q1/04 Revenues Growth Rate Cardizem LA 11,380 14,424 (21%) Teveten 5,481 4,679 17% Zovirax 27,120 27,853 (3%) Promoted Products 43,981 46,956 (6%) Wellbutrin XL 36,756 42,027 (13%) Biovail Pharmaceuticals Canada 25,039 22,935 9% Legacy Products 30,417 26,209 16% Generics 24,975 36,970 (32%) Total Product Revenues 161,168 175,097 (8%)
Pursuant to the agreements, Kos acquired Teveten (eprosartan mesylate), Teveten HCT (eprosartan mesylate/hydrochlorothiazide) and obtained exclusive sales and marketing rights to Cardizem LA (diltiazem hydrochloride) in the United States.
For the 12 months ended December 31, 2004, revenues for Cardizem LA were $53.
Its commercial portfolio of cardiovascular therapeutic products in the United States includes Cardizem LA, Cardizem CD, Tiazac, Vasotec, Vaseretic, Teveten, Teveten HCT, Isordil and a number of generic pharmaceutical products.